



AUG 15 1996

THE BRITISH JOURNAL OF PSYCHIATRY

August 1996

Vol. 169

Editorials

- China: the epidemiology of mental illness. *A. Kleinman* 129
- Scientific status of recovered memories. *C. R. Brewin* 131
- Genomics: the next psychiatric revolution? *A. Farmer and M. J. Owen* 135

Papers

- The mental health residential care study: classification of facilities and description of residents. *P. Lelliott, B. Audini, M. Knapp and D. Chisholm* 139
- The neural correlates of inner speech and auditory verbal imagery in schizophrenia: relationship to auditory verbal hallucinations. *P. K. McGuire, D. A. Silbersweig, I. Wright, R. M. Murray, R. S. J. Frackowiak and C. D. Frith* 148
- Life events and primary affective disorders. A one year prospective study. *D. Pardo, F. Bauwens, M. Dramaix, A. Tracy, C. Genevrois, L. Staner and J. Mendlewicz* 160
- The bereavement response: a cluster analysis. *W. Middleton, P. Burnett, B. Raphael and N. Martinek* 167
- The entry of mentally disordered people to the criminal justice system. *G. Robertson, R. Pearson and R. Gibb* 172

- Individual behavioural-cognitive therapy v. marital therapy for depression in maritally distressed couples. *L. Emanuels-Zuurveen and P. M. G. Emmelkamp* 181
- A controlled trial of cognitive-behavioural treatment of hypochondriasis. *H. M. C. Warwick, D. M. Clark, A. M. Cobb and P. M. Salkovskis* 189
- Body dysmorphic disorder. A survey of fifty cases. *D. Veale, A. Boocock, K. Gournay, W. Dryden, F. Shah, R. Willson and J. Walburn* 196
- Deliberate self-poisoning and self-injury in children and adolescents under 16 years of age in Oxford, 1976-1993. *K. Hawton, J. Fagg and S. Simkin* 202
- Symptoms of the schizophrenic negative syndrome. *V. Peralta and M. J. Cuesta* 209
- Age at onset in schizophrenia and risk of illness in relatives. Results from the Roscommon family study. *K. S. Kendler, L. Karkowski-Shuman and D. Walsh* 213
- Prevalence and cluster typology of maladaptive behaviours in a geographically defined population of adults with learning disabilities. *S. Smith, D. Branford, R. A. Collacott, S. A. Cooper and C. McGrother* 219
- Cumulative incidence and prevalence of childhood autism in children in Japan. *H. Honda, Y. Shimizu, K. Misumi, M. Niimi and Y. Ohashi* 228


continued p. ii

Published by The Royal College of Psychiatrists

ISSN 0007-1250

Now you can lift depression with the body in mind

Site-specific 'Cipramil' addresses four key dimensions of antidepressant therapy:



Cipramil
citalopram

Specifically treating depression

Abbreviated Prescribing Information

Presentation: 'Cipramil' tablets. PL 0458/0058, each containing 20mg of citalopram as the hydrobromide. 28 (OP) 20mg tablets £21.28.

Indications: Treatment of depressive illness in the initial phase and as maintenance against relapse/recurrence. **Dosage: Adults:** 20mg a day. Depending upon individual patient response, this may be increased in 20mg increments to a maximum of 60mg. Tablets should not be chewed, and should be taken as a single oral daily dose, in the morning or evening without regard for food. **Elderly:** 20mg a day increasing to a maximum of 40mg dependent upon individual patient response. **Children:** Not recommended. Restrict dosage to lower end of range in hepatic impairment. Dosage adjustment not necessary in cases of mild/moderate renal impairment. No information available in severe renal impairment (creatinine clearance <20ml/min). **Contra-indications:** Combined use of 5-HT agonists. Hypersensitivity to citalopram. **Pregnancy and Lactation:** Safety during human pregnancy and lactation has not been established. Use only if potential benefit outweighs possible risk. **Precautions:** Driving and operating machinery. History of mania. Caution in patients at risk of cardiac arrhythmias. Do not use with or within 14 days of MAO inhibitors: leave a seven day gap before starting MAO inhibitor treatment. **Drug Interactions:** MAO inhibitors (see Precautions). Use lithium and

tryptophan with caution. Routine monitoring of lithium levels need not be adjusted. Alcohol is not advised. **Adverse Events:** Most commonly nausea, sweating, tremor, somnolence and dry mouth. **Overdosage:** Symptoms have included somnolence, coma, sinus tachycardia, occasional nodal rhythm, episode of grand mal convulsion, nausea, vomiting, sweating and hyperventilation. No specific antidote. Treatment is symptomatic and supportive. Early gastric lavage suggested. **Legal Category:** POM 24.1.95. Further information available upon request. Product licence holder: Lundbeck Ltd, Sunningdale House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LF. 'Cipramil' is a trademark. © 1995 Lundbeck Ltd.

Date of preparation: May 1995

References

1. Hyttel J, XXII Nordiske Psykiater-Kongres, Reykjavik, 11 August, 1988: 11-21.
2. Eison AS et al. Psychopharmacology Bull 1990; 26 (3): 311-315.
3. Rosenberg C et al. Int Clin Psychopharmacol 1994; 9 (Suppl 1): 41-48.
4. Shaw DM et al. Br J Psychiatry 1986; 149: 515-517.
5. Bech P and Cialdella P. Int Clin Psychopharmacol 1992; 6 (Suppl 5): 45-54.
6. Sindrup SH et al. Ther Drug Monit 1993; 15: 11-17.
7. Van Harten J. Clin Pharmacokinet 1993; 24 (3): 203-220.

Lundbeck

Research for a better life

The British Journal of Psychiatry

August 1996

Volume 169

No. 2

Editor Greg Wilkinson

Senior Associate Editor

Alan Kerr *Newcastle upon Tyne*

Associate Editors

Sidney Crown *London*

Julian Leff *London*

Sir Martin Roth *Cambridge*

Sir Michael Rutter *London*

Peter Tyrer *London*

Editorial Advisers

Herschel Prins *Leicester*

Sir John Wood *Sheffield*

Kathleen Jones *York*

Assistant Editors

Mohammed Abou-Saleh *Al-Ain*

Louis Appleby *Manchester*

German Berrios *Cambridge*

Alistair Burns *Manchester*

Patricia Casey *Dublin*

John Cookson *London*

David Cottrell *Leeds*

Nigel Eastman *London*

Tom Fahy *London*

Anne Farmer *Cardiff*

Michael Farrell *London*

Nicol Ferrier *Newcastle upon Tyne*

William Fraser *Cardiff*

Richard Harrington *Manchester*

Sheila Hollins *London*

Jeremy Holmes *Barnstaple*

Alexander Kellam *Cardiff*

Peter Kennedy *York*

Michael King *London*

Alan Lee *Nottingham*

Shôn Lewis *Manchester*

Robin McCreadie *Dumfries*

Ian McKeith *Newcastle upon Tyne*

Roy McClelland *Belfast*

Stuart Montgomery *London*

David Owens *Leeds*

Ian Pullen *Edinburgh*

Rosalind Ramsay *London*

Henry Rollin *London*

Jan Scott *Newcastle upon Tyne*

Mike Shooter *Cardiff*

Andrew Sims *Leeds*

Jeanette Smith *Bristol*

George Stein *London*

David Tait *Perth*

Corresponding Editors

Sidney Bloch *Australia*

Patrice Boyer *France*

J.M. Caldas de Almeida *Portugal*

Andrew Cheng *Taiwan*

Andrei Cristian *Romania*

E. L. Edelstein *Israel*

Václav Filip *Czech Republic*

Heinz Katschnig *Austria*

Kenneth Kendler *USA*

Past Editors

Eliot Slater 1961–72 Edward H. Hare 1973–77 John L. Crammer 1978–83 Hugh L. Freeman 1984–93

Founded by J. C. Bucknill in 1853 as the *Asylum Journal* and known as the *Journal of Mental Science* from 1858 to 1963

Published by the Royal College of Psychiatrists



Toshi Kitamura *Japan*

Arthur Kleinman *USA*

F. Lieh Mak *Hong Kong*

Jair Mari *Brazil*

Harold Merskey *Canada*

Paul Mullen *Australia*

Ahmed Okasha *Egypt*

Volodymer Poltavetz *Ukraine*

Michele Tansella *Italy*

Toma Tomov *Bulgaria*

John Tsiantis *Greece*

J. L. Vázquez-Barquero *Spain*

Richard Warner *USA*

Statistical Adviser

Pak Sham *London*

Staff

Publications Manager

Dave Jago

Scientific Editor

Lesley Bennun

Assistant Scientific Editor

Dinah Alam

Editorial Assistants

Zofia Ashmore

Julia Burnside

Marketing Assistant

Dominic Bentham

Contents continued from front cover

Physical and psychiatric comorbidity in general practice. <i>S. R. Kisely and D. P. Goldberg</i>	236
A genetic linkage study of the D ₂ dopamine receptor locus in heavy drinking and alcoholism. <i>C. C. H. Cook, G. Palsson, A. Turner, D. Holmes, P. Brett, D. Curtis, H. Petursson and H. M. D. Gurling</i>	243
Columns	
Correspondence	249
One hundred years ago	254
Book reviews	255
<i>American Journal of Psychiatry</i> (contents)	257

Next month in the BJP

Community psychiatry: central policy, local implementation. *J. C. O'Grady*
Factitious illness (Munchausen syndrome) by proxy. *C. Bools*
Fragile states of mind: neuroticism, vulnerability and the long-term outcome of depression. *P. G. Surtees and N. W. J. Wainwright*
An index of need for psychiatric services based on in-patient utilisation. *P. Smith, T. A. Sheldon and S. Martin*

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists (a registered charity, registration number 228636). The *BJP* publishes original work in all fields of psychiatry. All communications, including manuscripts for publication, should be sent to the Editor, *British Journal of Psychiatry*, 17 Belgrave Square, London SW1X 8PG.

Full instructions to authors are given at the beginning of the January and July issues.

Subscriptions

Non-members of the College should contact the Publications Subscription Department, Royal Society of Medicine Press Limited, PO Box 9002, London W1A 0ZA (tel. 0171 290 2928; fax 0171 290 2929). Annual subscription rates for 1996 (12 issues post free) are as follows:

Europe (& UK): institutions £160, individuals £140
US: institutions \$310, individuals \$230
Elsewhere: institutions £190, individuals £150
Full airmail is £36/US\$64 extra.
Single copies of the Journal are £14, \$25 (post free).

Payment should be made out to the British Journal of Psychiatry.

Queries from non-members about missing or faulty copies should be addressed within six months to the same address; similar queries from College members should be addressed to the Registration Subscription Department, The Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.

© 1996 The Royal College of Psychiatrists. Unless so stated, material in the *British Journal of Psychiatry* does not necessarily reflect the views of the Editor or the Royal College of Psychiatrists. The publishers are not responsible for any error of omission or fact.

Back issues

Back issues published before 1995 may be purchased from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent (tel. 01303 850 101).

Advertising

Correspondence and copy should be addressed to Peter T. Mell, Advertising Manager, PTM Publishers Ltd, 282 High Street, Sutton, Surrey SM1 1PQ (tel. 0181 642 0162; fax 0181 643 2275).

US Mailing Information


The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists. Subscription price is \$295. Second class postage paid at Rahway, NJ. Postmaster send address corrections to the *British Journal of Psychiatry*, c/o Mercury Airfreight International Ltd Inc., 2323 Randolph Avenue, Avenel, New Jersey 07001.

©™ The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences – Permanence of Paper for Printed Library Materials. ANSI Z39.48–1984.

Typeset by Dobbie Typesetting Ltd, Tavistock, and Henry Ling Ltd.

Printed by Henry Ling Ltd, The Dorset Press, 23 High East Street, Dorchester, Dorset DT1 1HD.

New Brief Pulse ECT with *Computer-Assisted* Easy Seizure Monitoring



Somatics Thymatron™ DGx

- Automatically monitors your choice of EEG-EEG, EEG-ECG, or EEG-EMG and determines EEG and motor seizure lengths.
- Computer-measured seizure quality, including postictal EEG suppression, seizure energy index.
- Up to 8 seconds stimulus duration; pulsewidth as short as 0.5 ms.
- Single dial sets stimulus charge by age; high-dose option available.
- FlexDial™ adjusts pulsewidth and frequency without altering dose.

Distributed in the U.K. by:
DANTEC Electronics, Ltd.
Garonor Way
Royal Portbury
Bristol BS20 9XE
TEL (44) 1275-375333
FAX (44) 1275-375336

Distributed in Australia by:
MEECO Holdings Pty. Ltd.
10 Seville St.
North Parramatta NSW 2151
Australia
TEL (61) 2630-7755
FAX (61) 2630-7365

Distributed in New Zealand by:
WATSON VICTOR, Ltd.
4 Adelaide Rd.
Wellington, New Zealand
TEL (64) 4-385-7699
FAX (64) 4-384-4651

Distributed in India by:
DIAGNO.SYS
New Delhi
TEL (91) 11-644-0546
FAX (91) 11-622-9229

Distributed in Pakistan by:
IQBAL & CO.
Islamabad
TEL (92) 51-291078
FAX (92) 51-281623

Distributed in South Africa by:
DELTA SURGICAL
Craighall
TEL (27) 11-792-6120
FAX (27) 11-792-6926

Distributed in U.S.A. and Canada by:

 **SOMATICS, INC., 910 Sherwood Drive # 17, Lake Bluff, IL, 60044, U.S.A.**
Fax: (847) 234-6763; Tel: (847) 234-6761

**ST. GEORGE'S HOSPITAL MEDICAL SCHOOL
UNIVERSITY OF LONDON
CENTRE FOR ADDICTION STUDIES
DEPARTMENT OF ADDICTIVE BEHAVIOUR
COURSE PROGRAMME 1996/1997**

MSc in Addictive Behaviour

- A unique day-release course for professionals
- Part-time two year or one year full-time course leading to MSc in Addictive Behaviour (University of London)
- Course based on modular learning units and clectives
- Covers Drugs, Alcohol, Smoking, Eating Disorders, Gambling, Prevention, Service Provision and Treatment
- Offers clinical/fieldwork placements
- Applicants should be graduates or have a recognised professional qualification with three or more years' experience

Diploma in Addictive Behaviour

Part-time, one year (4 terms) leading to Diploma in Addictive Behaviour Accredited with professional bodies
for

(a) Multidisciplinary course

For specialist drug, alcohol and HIV workers
External/fieldwork placements

(b) General Practitioners course

Comprehensive training in the addictions in the primary health care setting Approved by the British Postgraduate Medical Federation for the Postgraduate Education Allowance

(c) Prison Medical Officers course

A unique course designed for Prison Medical Officers Comprehensive training in the addictions in the Prison Health Care setting

Course Director: Professor A. Hamid Ghodse

Further information and application details may be obtained by writing to the Course Secretary, Education and Training Unit, St George's Hospital Medical School, Department of Addictive Behaviour, Cranmer Terrace, Tooting, London SW17 0RE or Telephone 0181 725 2637 or 2781. Fax: 0181 725 2914

BASPCAN

British Association for the Study and Prevention of
Child Abuse and Neglect
Registered Charity no: 279119
Congress Office: PO Box 5517, Inverness IV1 2ZL Scotland

CALL FOR PAPERS

**Third National Congress
'APPROACHING THE MILLENNIUM'
The Future Shape of Child Protection
8-11 July 1997**

Venue: Heriot Watt University, Edinburgh Scotland

*The Scientific Committee invites you to submit a paper
for consideration. Papers are invited from all relevant
areas including*

**Social Work *Education *Medicine*

**Voluntary Agencies *International Perspectives *Law*

Abstract forms are available from the Congress Office
(as above) and the BASPCAN National Office,
10 Priory Street, York YO1 1EZ (Tel 01904 613605,
Fax 01904 642239).

Completed Abstract forms are to be returned to the
Congress Convenor, Congress Office by 1 November
1996. Written notification of whether papers are
accepted will be sent by 1 March 1997.

THIRD ANNUAL CONFERENCE

on

**GAY, LESBIAN AND BISEXUAL ISSUES
IN PSYCHIATRY**


**FEBRUARY 28th - MARCH 1st, 1997
SYDNEY, AUSTRALIA**

**FOR ARTICLE GUIDELINES OR TO
REGISTER INTEREST PLEASE CONTACT:**

**DR. MICHAEL S. ARMSTRONG
LEVEL 4, BEANBAH CHAMBERS
236 MACQUARIE STREET
SYDNEY NSW 2000
AUSTRALIA**

**TEL: +61 2 231 3230
FAX: +61 2 231 3117
EMAIL: msa@ozemail.com.au.**

THE CONSTANT CURRENT SERIES 5B E.C.T. APPARATUS



ECTONUS Constant Current Series 5B

Supplementing the Constant Current Series 5A ECT Apparatus

ECTONUS and ECTONUSTIM models available from the manufacturers with over 46 years of experience in the design of E.C.T. equipment.

ECTRON LTD

KNAP CLOSE LETCHWORTH HERTS ENGLAND SG6 1AQ
Telephone 01462 682124 Fax 01462 481463

New from Gaskell



Psychiatry for the Developing World

Edited by Digby Tantam, Louis Appleby & Alice Duncan

Written by psychiatrists from the developing world, this is an up-to-date and comprehensive multi-author volume on psychiatry as it can be practiced in developing countries today. All aspects of psychiatry are covered, including administrative, practical, and planning advice, training and conducting research. Recommendations on treatment of common psychiatric disorders are also provided, following ICD-10 classification standards. Price £25.00, 376pp., 1996, ISBN 0 902241 86 9


Available from good bookshops and from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. 0171-235 2351, extension 146)

—EFEXOR—

THE WORLD'S FIRST

S · N · R · I

SEROTONIN NORADRENALINE REUPTAKE INHIBITOR



Space photographs provided courtesy of National Aeronautics and Space Administration, NASA


The result of original Wyeth research and development, Efexor (venlafaxine) is the first of a new class of antidepressants, the SNRIs.

Efexor is a serotonin and noradrenaline reuptake inhibitor and increases the availability of both of the key neurotransmitters involved in depression.¹ This is in line with current thinking on the pathophysiology of depression, which stresses the importance of interactions between serotonin and noradrenaline.²

Extensive clinical trials of Efexor in over 2,500 depressed patients have confirmed the success of this approach. Efexor has been shown to be at least as effective and better tolerated than standard tricyclic and related antidepressants such as dothiepin, imipramine and trazodone.³

Efexor has also been shown to compare favourably with the SSRI fluoxetine in inpatient⁴ and outpatient studies.⁵ Furthermore, Efexor demonstrates a significant dose response curve which allows flexibility of treatment in a wide range of patients.⁶

For many depressed patients, the world's first SNRI could make a world of difference.

EFEXOR * 
VENLAFAXINE 37.5mg b.d.

EFFECTIVE IN A WIDE RANGE OF DEPRESSED PATIENTS

PRESCRIBING INFORMATION PRESENTATION Tablets containing 37.5mg, 50mg or 75mg venlafaxine (as hydrochloride). USE Treatment of depressive illness. DOSAGE Usually 75mg/day (37.5mg b.d.) with food, increasing to 150mg/day (75mg b.d.) if necessary. In more severely depressed patients, 150mg/day (75mg b.d.) increasing every 2 or 3 days in up to 75mg/day increments to a maximum of 375mg/day, then reducing to usual dose consistent with patient response. Discontinue gradually. Elderly use normal adult dose. Doses should be reduced by 50% for moderate renal or moderate hepatic impairment. CONTRA-INDICATIONS Pregnancy, lactation, concomitant use with MAOIs, hypersensitivity to venlafaxine or other components, patients aged below 18 years. PRECAUTIONS Use with caution in patients with myocardial infarction, unstable heart disease, renal or hepatic impairment, or a history of epilepsy (discontinue in event of seizure). Patients should not drive or operate machinery if their ability to do so is

impaired. Possibility of postural hypotension (especially in the elderly). Women of child-bearing potential should use contraception. Prescribe smallest quantity of tablets according to good patient management. Monitor blood pressure with doses >200mg/day. Advise patients to notify their doctor should an allergy develop or if they become or intend to become pregnant. Use with caution in patients taking other CNS-active drugs or in the elderly or hepatically-impaired patients taking cimetidine. Patients with a history of drug abuse should be monitored carefully. Not recommended in severe renal or severe hepatic impairment. INTERACTIONS MAOIs do not use Efexor in combination with MAOIs or within 14 days of stopping MAOI treatment. Allow 7 days after stopping Efexor before starting a MAOI. SIDE EFFECTS Nausea, headache, insomnia, somnolence, dry mouth, dizziness, constipation, asthenia, sweating, nervousness, anorexia, dyspepsia, abdominal pain, anxiety, impotence, abnormality of accommodation,

vasodilation, vomiting, tremor, paraesthesia, abnormal ejaculation/orgasm, chills, hypertension, palpitation, weight gain, agitation, decreased libido, rise in blood pressure, postural hypotension, reversible increases in liver enzymes, slight increase in serum cholesterol. BASIC NHS PRICE 37.5mg tablet (PL 0011/0199) – Calendar pack of 56 tablets £23.97, 50mg tablet (PL 0011/0200) – Blister pack of 42 tablets £23.97, 75mg tablet (PL 0011/0201) – Calendar pack of 56 tablets £39.97. LEGAL CATEGORY POM. Further information is available upon request. PRODUCT LICENCE HOLDER: Wyeth Laboratories (John Wyeth & Brother Limited), Taplow, Maidenhead, Berkshire SL6 0PH. REFERENCES 1 Clerc GE *et al* Int Clin Psychopharmacol 1994; 9: 139-142. 2 Kalus O, Asnis GH, van Praag HM, Psychiatric Annals 1989; 19: 348-353. 3 Data on file, Medical Affairs Department, Wyeth-Ayerst International Inc. Date of Preparation December 1995. Code Z773520/09/95. * trade marks

Z773520/09/95